Dr Kayleigh Griffiths completed her undergraduate degree in Pharmacology in 2011, before moving on to complete a Masters in Cardiovascular health and disease in 2012, both at the University of Manchester, UK.
In 2017, Kayleigh completed her PhD at Queen’s University Belfast, focussing on the effects of serum amyloid A and lymphocyte activation gene 3 in cardiovascular disease and diabetes.
After her PhD, Kayleigh continued working as a researcher at Queen’s University where she was involved in two studies, PRIME STUDY (A Longitudinal Investigation of Periodontal Disease as a Risk Factor for Coronary Heart Disease and Stroke) and NICOLA (Northern Ireland cohort of longitudinal aging).
In 2018, Kayleigh joined the University of Birmingham as a Post-doctoral researcher in the Institute of Cardiovascular Sciences. Kayleigh works under the supervision of Dr Melanie Madhani in the translational research group. This group aims to assess novel pharmacological strategies to protect the heart against ischaemia reperfusion injury and heart failure.
Kayleigh is part of the committee aimed at delivering the BHF Accelerator Award given to the University of Birmingham.